NeurogesX, Inc. (NGSX) - OTCPK - No Info
  • Oct. 7, 2014, 9:54 AM
    • Menlo Park, CA-based Virobay (VBAY) is set for its IPO of 3.8M shares at $12 - 14.
    • The clinical stage biopharmaceutical firm develops drugs based on its cysteine cathepsin platform. Cysteine cathepsins are important enzymes in the biology of many diseases. The company believes that inhibiting these enzymes produces safer, more effective therapies. It currently focuses its efforts on inhibitors of cathepsins S and B.
    • Its lead product candidates are cathepsin S inhibitors: VBY-036 for neuropathic pain and Crohn's disease and VBY-891 for psoriasis. Phase 2 development for all three indications should commence in 1H 2015 which means that meaningful product revenues are far in the distance.
    • In 2013, the company generated $9.9M in collaboration revenue. Its operating loss was ($2.3M). In 1H 2015, collaboration revenue dropped to $1.1M and the loss from operations increased to ($3.6M).
    • S-1
    • Crohn's disease-related tickers: (ABBV -1.6%)(MRK -1.2%)(RDHL +0.4%)(VBLX)(OTCPK:TKPHF)(OTCPK:TKPYY)(CNDO +1.1%)(OTCQB:SNGX)(PSTI +2.3%)
    • Neuropathic pain-related tickers: (DARA -4.4%)(AVNR -3.4%)(ZLCS +0.9%)(IPCI -2%)(BLRX -1.9%)(MNOV +0.6%)(PFE -0.3%)(OTCPK:NGSX)
    • Psoriasis-related tickers: (DERM -0.5%)(NVS -2.5%)(CELG -1.4%)(LLY -1.3%)(CANF -2.3%)(IDRA -1.4%)(JNJ -0.8%)(XNPT +0.5%)(HSP -0.2%)
    | Oct. 7, 2014, 9:54 AM
  • Jul. 9, 2013, 8:32 AM

    Acorda Therapeutics (ACOR) has acquired the rights in the Americas and certain other territories to two nerve pain treatments from NeurogesX (NGSX.OB) - FDA approved Qutenza and "Phase III ready" NP-1998. Acorda paid $8M up front and will pay as much as $5m in milestones related to NP-1998. (PR)

    | Jul. 9, 2013, 8:32 AM
  • Apr. 11, 2012, 11:04 AM

    Shares of microcap drug developer NeurogesX (NGSX +30%) soar after saying the FDA has accepted its request for a meeting to discuss ongoing clinical studies of NGX-1998, its product candidate for neuropathic pain. Phase 2 studies were completed at the end of 2011.

    | Apr. 11, 2012, 11:04 AM
  • Feb. 10, 2012, 10:20 AM

    NeurogesX (NGSX) -20.6% after yesterday's news that an FDA advisory committee did not recommend approval for its Qutenza patch as a treatment for nerve pain related to HIV-associated peripheral neuropathy.

    | Feb. 10, 2012, 10:20 AM
  • Feb. 9, 2012, 2:36 PM
    A FDA panel votes 12 to 0 that the Qutenza patch offered by NeurogesX (NGSX) doesn't treat pain in patients afflicted with HIV. Shares are still under a trading halt.
    | Feb. 9, 2012, 2:36 PM
  • Feb. 9, 2012, 8:35 AM
    Trading in both Astex Pharmaceuticals (ASTX) and NeurogesX (NGSX) is halted ahead of a FDA panel meeting on separate drugs for the firms. (FDA agenda: ASTX, NGSX)
    | Feb. 9, 2012, 8:35 AM
  • Feb. 7, 2012, 8:58 AM

    NeurogesX (NGSX) -21.9% premarket following cautious reports related to FDA approval of its patch for HIV pain. The prescription-strength capsaicin patch didn’t meet its goals in studies for reducing pain caused by neuropathy linked to the virus, an FDA report says.

    | Feb. 7, 2012, 8:58 AM
  • Nov. 17, 2009, 9:00 AM

    Premarket gainers: SMTL +30%. AGO +12%. HLCS +12%. CSE +11%. APWR +11%. DDS +10%. NGSX +9%. SINA +7%. SKS +6%. EJ +6%. CTIC +6%. DPTR +5%. MPEL +4%.
    Losers: PSUN -22%. SPWRA -16%. JEC -10%. AOB -9%. BCRX -9%. IRE -9%. CPSL -8%. SII -7%. AIB -7%. NLST -6%. TGP -6%. HOLX -5%. THOR -4%.

    | Nov. 17, 2009, 9:00 AM | 1 Comment
Company Description
NeurogesX, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.<br /><br />The Company's lead product, Qutenza?, is currently approved... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States